Literature DB >> 19804606

MSH6 syndrome.

Janina Suchy1, Jan Lubinski.   

Abstract

Entities:  

Year:  2008        PMID: 19804606      PMCID: PMC2735474          DOI: 10.1186/1897-4287-6-2-103

Source DB:  PubMed          Journal:  Hered Cancer Clin Pract        ISSN: 1731-2302            Impact factor:   2.857


× No keyword cloud information.

The MSH6 gene in collaboration with MSH2, MLH1, MSH3, PMS1 and PMS2 genes is involved in one of the systems repairing the errors that arise during DNA replication, called the "methyl directed mismatch repair" system [1-3]. hMLH1 and hMSH2 mutations give rise most frequently to the classical Lynch syndrome (HNPCC) [4-6]. hMSH6 mutations often occur in clinically less typical HNPCC families, that do not fulfil the Amsterdam criteria [7-11]. So far more than 200 families with germline hMSH6 mutation have been described . Characteristic features of families with hMSH6 mutation are: • higher risk for colorectal cancer (~70% for men and ~30% for females), endometrial cancer (~70%) and also for ovarian, upper urinary tract, stomach and breast cancer [12], • higher incidence of extracolonic cancers, when compared with HNPCC families [13], • later age at onset of cancers, e.g. for colorectal cancer the mean age at diagnosis is ~56 years, for endometrial cancer ~54 years and for ovarian cancer ~49 years [12,13], • frequent left-sided localization of colorectal cancer [9]. The prevalence of hMSH6 constitutional mutations in families that fulfil the Amsterdam criteria is about 5-10% [8,9]. Because the frequency of hMSH6 mutations in other groups is not precisely determined, we recommend the following diagnostic procedure for hMSH6 mutation detection: • selection of families with colorectal, endometrial, ovarian, urinary tract and/or stomach, breast cancer aggregation, • immunohistochemical analysis (IHC) of hMSH6 protein expression in tumour colorectal or endometrial tissue [14-16], • in cases of hMSH6-negative tumours, DHPLC/sequencing of the coding regions of the hMSH6 gene. Among the reported hMSH6 mutations about 30 are recurrent, i.e. they are detected in more than one family [17-19]. Probably in the near future diagnostic tests will be described to allow cheap, simple and fast detection of mutations showing a "founder effect" characteristic for particular ethnic groups.

Surveillance protocol

As yet a suitable surveillance programme in hMSH6 families based on prospective family trials is not available. In our centre we offer the following surveillance protocol: colorectal cancer - colonoscopy every 2 to 3 years beginning at least 15 years before the earliest age of onset in the family, endometrial cancer - annual transvaginal ultrasound scan starting at least 15 years before the earliest age of onset in the family, • screening for other cancers depending on the tumour spectrum in the family.

Surgical management

Because of the described higher risk of developing multiple (synchronous and metachronous) cancers and also endometrial cancer in females after age of 50 years in hMSH6 mutation carriers [12,17,20], it is recommended to take into consideration surgical treatment similar to that for patients with CRC associated with Lynch syndrome, i.e. colectomy with ileorectal anastomosis, extended by prophylactic hysterectomy and oophorectomy for women over 50 years old.
  20 in total

1.  Involvement of hMSH6 in the development of hereditary and sporadic colorectal cancer revealed by immunostaining is based on germline mutations, but rarely on somatic inactivation.

Authors:  Jens Plaschke; Stefan Krüger; Steffen Pistorius; Franz Theissig; Hans D Saeger; Hans K Schackert
Journal:  Int J Cancer       Date:  2002-02-10       Impact factor: 7.396

Review 2.  Do MSH6 mutations contribute to double primary cancers of the colorectum and endometrium?

Authors:  G S Charames; A L Millar; T Pal; S Narod; B Bapat
Journal:  Hum Genet       Date:  2000-12       Impact factor: 4.132

Review 3.  Genetic susceptibility to non-polyposis colorectal cancer.

Authors:  H T Lynch; A de la Chapelle
Journal:  J Med Genet       Date:  1999-11       Impact factor: 6.318

4.  Ovarian cancer of endometrioid type as part of the MSH6gene mutation phenotype.

Authors:  Janina Suchy; Grzegorz Kurzawski; Anna Jakubowska; Jan Lubiński
Journal:  J Hum Genet       Date:  2002       Impact factor: 3.172

Review 5.  DNA mismatch repair and mutation avoidance pathways.

Authors:  Thomas M Marti; Christophe Kunz; Oliver Fleck
Journal:  J Cell Physiol       Date:  2002-04       Impact factor: 6.384

6.  Atypical HNPCC owing to MSH6 germline mutations: analysis of a large Dutch pedigree.

Authors:  A Wagner; Y Hendriks; E J Meijers-Heijboer; W J de Leeuw; H Morreau; R Hofstra; C Tops; E Bik; A H Bröcker-Vriends; C van Der Meer; D Lindhout; H F Vasen; M H Breuning; C J Cornelisse; C van Krimpen; M F Niermeijer; A H Zwinderman; J Wijnen; R Fodde
Journal:  J Med Genet       Date:  2001-05       Impact factor: 6.318

7.  Molecular and clinical characteristics of MSH6 variants: an analysis of 25 index carriers of a germline variant.

Authors:  Maran J W Berends; Ying Wu; Rolf H Sijmons; Rob G J Mensink; Tineke van der Sluis; Jannet M Hordijk-Hos; Elisabeth G E de Vries; Harry Hollema; Arend Karrenbeld; Charles H C M Buys; Ate G J van der Zee; Robert M W Hofstra; Jan H Kleibeuker
Journal:  Am J Hum Genet       Date:  2002-01       Impact factor: 11.025

8.  Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: the German Hereditary Nonpolyposis Colorectal Cancer Consortium.

Authors:  Jens Plaschke; Christoph Engel; Stefan Krüger; Elke Holinski-Feder; Constanze Pagenstecher; Elisabeth Mangold; Gabriela Moeslein; Karsten Schulmann; Johannes Gebert; Magnus von Knebel Doeberitz; Josef Rüschoff; Markus Loeffler; Hans K Schackert
Journal:  J Clin Oncol       Date:  2004-10-13       Impact factor: 44.544

9.  Microsatellite instability in colorectal carcinoma. The comparison of immunohistochemistry and molecular biology suggests a role for hMSH6 [correction of hMLH6] immunostaining.

Authors:  Valérie Rigau; Nicole Sebbagh; Sylviane Olschwang; François Paraf; Najat Mourra; Yann Parc; Jean-François Flejou
Journal:  Arch Pathol Lab Med       Date:  2003-06       Impact factor: 5.534

10.  Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance.

Authors:  Yvonne M C Hendriks; Anja Wagner; Hans Morreau; Fred Menko; Astrid Stormorken; Franz Quehenberger; Lodewijk Sandkuijl; Pal Møller; Maurizio Genuardi; Hans Van Houwelingen; Carli Tops; Marjo Van Puijenbroek; Paul Verkuijlen; Gemma Kenter; Anneke Van Mil; Hanne Meijers-Heijboer; Gita B Tan; Martijn H Breuning; Riccardo Fodde; Juul Th Wijnen; Annette H J T Bröcker-Vriends; Hans Vasen
Journal:  Gastroenterology       Date:  2004-07       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.